ADCY1 Up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with ADCY1 Up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with ADCY1 Up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with ADCY1 Up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with ADCY1 Up.

Results found

Linked to

 

Label

Description

 

Gene

ENSG00000135002 - riboflavin kinase

Gene

ENSG00000133731 - inositol monophosphatase 1

Gene

ENSG00000144048 - dual specificity phosphatase 11

Gene

ENSG00000148935 - growth arrest specific 2

Gene

ENSG00000115263 - glucagon

Gene

ENSG00000183291 - selenoprotein F

Gene

ENSG00000112818 - meprin A subunit alpha

Gene

ENSG00000115540 - MOB family member 4, phocein

Gene

ENSG00000137947 - general transcription factor IIB

Gene

ENSG00000162980 - ARF like GTPase 5A

  • Gene

    ENSG00000135002 - riboflavin kinase


  • Gene

    ENSG00000133731 - inositol monophosphatase 1


  • Gene

    ENSG00000144048 - dual specificity phosphatase 11


  • Gene

    ENSG00000148935 - growth arrest specific 2


  • Gene

    ENSG00000115263 - glucagon


  • Gene

    ENSG00000183291 - selenoprotein F


  • Gene

    ENSG00000112818 - meprin A subunit alpha


  • Gene

    ENSG00000115540 - MOB family member 4, phocein


  • Gene

    ENSG00000137947 - general transcription factor IIB


  • Gene

    ENSG00000162980 - ARF like GTPase 5A

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.